Studies on the predictors of severity in drug reaction with eosinophilia and systemic symptoms in different population groups may enable us to identify the warning signs and help to formulate the standard therapeutic guidelines.

Similar responses were observed across various prior therapy types. Additional analysis of efficacy will be provided for mutation status and CNS activity in both cohorts. Conclusion: Clinical activity was observed in previously treated patiens in both NSCLC EGFR or HER2 exon 20 mutations regardless of specific mutations and prior therapy with consistent responses seen in more heavily pre-treated patients. The safety data shows a manageable toxicity profile that is typical of 2nd generation TKIs. Additional cohorts are enrolling with alternative dose levels and BID dosing.

No abstract

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

No abstract